APRT Inhibitors are a specialized class of chemical compounds designed to specifically target and inhibit the activity of the APRT (Adenine Phosphoribosyltransferase) enzyme. APRT is a key enzyme in the purine salvage pathway, a metabolic pathway that recycles purines to synthesize nucleotides. Specifically, APRT catalyzes the conversion of adenine and phosphoribosyl pyrophosphate (PRPP) into adenosine monophosphate (AMP), a crucial step that helps maintain the balance of nucleotides within the cell. By facilitating the reuse of adenine, APRT plays an essential role in cellular metabolism and the maintenance of nucleotide pools. APRT Inhibitors function by binding to the active site of the enzyme, where they can either compete with adenine or PRPP or interfere with the enzyme's catalytic mechanism. This binding effectively blocks the conversion process, disrupting the purine salvage pathway and altering the availability of nucleotides in the cell.
The design and effectiveness of APRT Inhibitors are closely tied to their chemical properties and molecular architecture. These inhibitors are often engineered to mimic the structure of adenine or PRPP, allowing them to competitively bind to the enzyme's active site and prevent the natural substrates from interacting with APRT. The inhibitors may include specific functional groups that enhance their binding affinity through hydrogen bonding, van der Waals interactions, or electrostatic interactions with key residues within the enzyme. Additionally, hydrophobic regions within the inhibitor's structure may interact with non-polar pockets of the enzyme, further stabilizing the inhibitor-enzyme complex. The solubility, stability, and bioavailability of these inhibitors are optimized to ensure they can effectively reach and act on APRT in the cellular environment. Furthermore, the kinetics of binding, such as the rates of association and dissociation, are crucial factors that determine the potency and duration of inhibition. By studying the interactions between APRT Inhibitors and the enzyme, researchers can gain valuable insights into the regulation of the purine salvage pathway and the broader implications of modulating nucleotide metabolism within the cell. Understanding these interactions is essential for elucidating how APRT contributes to cellular homeostasis and the potential consequences of its inhibition on various biological processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $131.00 | ||
Inhibits xanthine oxidase, potentially reducing the availability of adenine, a substrate for APRT. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Dihydrofolate reductase inhibitor, leads to decreased purine nucleotide synthesis, indirectly affecting APRT substrate availability. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $72.00 $104.00 | ||
Purine analogue that can be incorporated into nucleic acids, possibly affecting the balance of purine metabolism and subsequently APRT activity. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Prodrug of 6-mercaptopurine, and by similar mechanism, can modulate purine metabolism and indirectly APRT activity. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $69.00 $266.00 | 8 | |
Inhibits inosine monophosphate dehydrogenase, potentially altering purine nucleotide pools and affecting APRT activity. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $63.00 $110.00 $214.00 | 1 | |
Inhibits inosine monophosphate dehydrogenase, could indirectly influence APRT through purine nucleotide depletion. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $78.00 $260.00 | 18 | |
Ribonucleotide reductase inhibitor, may lead to imbalances in deoxyribonucleotide pools, indirectly affecting APRT activity. | ||||||
Clofarabine | 123318-82-1 | sc-278864 sc-278864A | 10 mg 50 mg | $185.00 $781.00 | ||
Purine nucleoside analogue that inhibits ribonucleotide reductase, could indirectly decrease APRT activity by affecting nucleotide synthesis. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Purine nucleoside analogue, inhibits DNA polymerase and ribonucleotide reductase, may indirectly influence APRT by altering nucleotide synthesis and repair. | ||||||
2-Chloro-2′-deoxyadenosine | 4291-63-8 | sc-202399 | 10 mg | $144.00 | 1 | |
Purine nucleoside analogue, which interferes with DNA synthesis and repair, potentially altering APRT activity indirectly. | ||||||